Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trever G Bivona

Showing results (1-10 of 147) with videos related to

Pageof 15
Sort By:
Science (New York, N.Y.)|March 23, 2019
Dampening oncogenic RAS signalingTrever G Bivona
Cancer Discovery|April 4, 2024
Phase-Separated Biomolecular Condensation in Cancer: New Horizons and Next FrontiersTrever G Bivona
Journal of Thoracic Disease|July 10, 2020
EGFR targeted therapy resistance: current status, challenges, and future outlookTrever G Bivona
Translational Cancer Research|January 8, 2019
Dividing and conquering the variation among variants in <i>EML4-ALK</i> lung cancerTrever G Bivona
Molecular & Cellular Oncology|June 17, 2016
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitorsLuping Lin, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|December 15, 2015
RAS-MAPK in ALK targeted therapy resistanceGorjan Hrustanovic, Trever G Bivona
Cancer Cell|June 25, 2021
Stepwise evolution of therapy resistance in AMLPhilippe Gui, Trever G Bivona
Molecular & Cellular Oncology|June 17, 2016
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancerGorjan Hrustanovic, Trever G Bivona
Small Gtpases|February 23, 2016
RAS signaling in ALK fusion lung cancerGorjan Hrustanovic, Trever G Bivona
The Journal of Clinical Investigation|February 15, 2022
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancerTadashi Manabe, Trever G Bivona
Pageof 15

Showing results (1-10 of 147) with videos related to

Sort By:
Pageof 15
Science (New York, N.Y.)|March 23, 2019
Dampening oncogenic RAS signalingTrever G Bivona
Cancer Discovery|April 4, 2024
Phase-Separated Biomolecular Condensation in Cancer: New Horizons and Next FrontiersTrever G Bivona
Journal of Thoracic Disease|July 10, 2020
EGFR targeted therapy resistance: current status, challenges, and future outlookTrever G Bivona
Translational Cancer Research|January 8, 2019
Dividing and conquering the variation among variants in <i>EML4-ALK</i> lung cancerTrever G Bivona
Molecular & Cellular Oncology|June 17, 2016
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitorsLuping Lin, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|December 15, 2015
RAS-MAPK in ALK targeted therapy resistanceGorjan Hrustanovic, Trever G Bivona
Cancer Cell|June 25, 2021
Stepwise evolution of therapy resistance in AMLPhilippe Gui, Trever G Bivona
Molecular & Cellular Oncology|June 17, 2016
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancerGorjan Hrustanovic, Trever G Bivona
Small Gtpases|February 23, 2016
RAS signaling in ALK fusion lung cancerGorjan Hrustanovic, Trever G Bivona
The Journal of Clinical Investigation|February 15, 2022
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancerTadashi Manabe, Trever G Bivona
Pageof 15